Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01875666
Title Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center

Her2-receptor positive breast cancer


Lapatinib + Trastuzumab



Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35294 United States Details
IU Simon Cancer Center Indianapolis Indiana 46202 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Lineberger Comprehensive Cancer Center, UNC Chapel Hill North Carolina 27599 United States Details
MD Anderson Houston Texas 77030-4008 United States Details
*Shaded cells indicate that there was no data available from for the field